Enzyme replacement therapy for hypophosphatasia-The current paradigm.

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Hypophosphatasia (HPP) is a rare inherited metabolic disorder.
• Characterized by impaired skeletal mineralization and low tissue nonspecific serum alkaline phosphatase (TNSALP) activity.
• Caused by mutations in the gene encoding TNSALP, leading to a broad phenotype including skeletal abnormalities, developmental issues, and premature death.

Purpose of the Study:

• To review preclinical data and clinical trial findings for asfotase alfa.
• To highlight the efficacy of asfotase alfa as a treatment for Hypophosphatasia.
• To emphasize the importance of an interdisciplinary approach in managing HPP with asfotase alfa.

Main Methods:

• Review of preclinical studies on asfotase alfa.
• Analysis of data from clinical trials involving asfotase alfa.
• Compilation of case reports on asfotase alfa treatment for HPP.

Main Results:

• Asfotase alfa is a fully humanized, recombinant enzyme replacement therapy.
• It is approved in several countries for severe forms of HPP (perinatal and infantile).
• Clinical data demonstrate a transformative effect of asfotase alfa in HPP management.

Conclusions:

• Asfotase alfa represents a significant advancement in HPP treatment.
• The enzyme replacement therapy shows efficacy in improving outcomes for HPP patients.
• Integrated, interdisciplinary care models enhance the effectiveness of asfotase alfa therapy.